Clinical Study Involving Liposomal Glutathione Published

Published July, 2015

The tenth study involving Liposomal Glutathione has been published. The clinical study, Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals, was published in July, 2015 online and in the Journal of Interferon & Cytokine Research.

Gluthione Study - Read in PDF

Where to Read the Study

The study can read in full on

View the full PDF here.

PubMed ID: 26133750

Study Summary

The clinical study was conducted at a university clinic. Individuals involved with the study had low glutathione related to HIV and the study showed that low glutathione is associated with a decrease in defensive function of immune cells. Furthermore, direct support using oral Liposomal Glutathione restores TH1 cell function and supports immune cell function related to fighting infection.

Glutathione Levels Pre- and Post-Supplementation

In Addition, the clinical study showed the role of glutathione in immune support. Th1 lymphocytes are critical in the cellular immune response and they play an important role in host defense system against microbial agents and viruses. In this study, tuberculosis bacteria were introduced into the participant’s immune cells in the lab. As a result, the growth of TB was significantly reduced in their cells after ingesting oral Liposomal Glutathione.

The red in the graph represents TB growth in the immune cells.